Berenberg Bank started coverage on shares of Certara (NASDAQ:CERT – Get Rating) in a report released on Thursday, The Fly reports. The firm issued a buy rating and a $23.00 target price on the stock.
A number of other analysts have also recently weighed in on CERT. SVB Leerink reduced their target price on shares of Certara from $29.00 to $26.00 and set an outperform rating for the company in a report on Wednesday, August 10th. Credit Suisse Group initiated coverage on shares of Certara in a report on Wednesday, August 24th. They set an outperform rating and a $22.00 target price for the company. Barclays reduced their target price on shares of Certara from $24.00 to $21.00 and set an overweight rating for the company in a report on Wednesday, August 17th. Piper Sandler reduced their target price on shares of Certara from $28.00 to $25.00 and set an overweight rating for the company in a report on Wednesday, August 10th. Finally, Morgan Stanley reduced their target price on shares of Certara from $24.00 to $20.00 and set an equal weight rating for the company in a report on Wednesday, August 24th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Certara currently has a consensus rating of Moderate Buy and an average target price of $26.13.
Get
Certara alerts:
Certara Price Performance
CERT opened at $16.28 on Thursday. The firm has a market cap of $2.60 billion, a price-to-earnings ratio of -271.33, a price-to-earnings-growth ratio of 1.02 and a beta of 1.27. Certara has a fifty-two week low of $14.94 and a fifty-two week high of $45.48. The company's 50-day moving average price is $19.78 and its 200 day moving average price is $20.07. The company has a quick ratio of 3.51, a current ratio of 3.51 and a debt-to-equity ratio of 0.28.
Certara (NASDAQ:CERT – Get Rating) last posted its quarterly earnings data on Tuesday, August 9th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.02). The company had revenue of $82.00 million during the quarter, compared to the consensus estimate of $85.46 million. Certara had a negative net
margin of 3.14% and a positive return on equity of 4.26%. The company's revenue was up 17.0% on a year-over-year basis. During the same quarter last year, the business earned $0.03 earnings per share. As a group, sell-side analysts expect that Certara will post 0.28 earnings per share for the current year.
Insiders Place Their Bets
In other Certara news, Director Stephen M. Mclean purchased 20,000 shares of the business's stock in a transaction dated Friday, August 19th. The shares were acquired at an average price of $16.32 per share, for a total transaction of $326,400.00. Following the acquisition, the director now owns 42,000 shares of the company's stock, valued at $685,440. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Certara news, CFO Michael Andrew Schemick acquired 25,000 shares of Certara stock in a transaction dated Wednesday, August 17th. The stock was bought at an average cost of $16.64 per share, with a total value of $416,000.00. Following the acquisition, the chief financial officer now owns 517,870 shares of the company's stock, valued at $8,617,356.80. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Stephen M. Mclean acquired 20,000 shares of Certara stock in a transaction dated Friday, August 19th. The shares were acquired at an average cost of $16.32 per share, with a total value of $326,400.00. Following the completion of the acquisition, the director now directly owns 42,000 shares in the company, valued at approximately $685,440. The disclosure for this purchase can be found here. Insiders sold a total of 6,196,893 shares of company stock worth $107,705,300 in the last quarter. 4.02% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Certara
Institutional investors have recently added to or reduced their stakes in the company. EQT Fund Management S.a r.l. bought a new position in shares of Certara in the second quarter worth about $771,679,000. Clearbridge Investments LLC grew its position in shares of Certara by 58.7% during the 1st quarter. Clearbridge Investments LLC now owns 3,200,895 shares of the company's stock worth $68,755,000 after buying an additional 1,183,859 shares during the period. William Blair Investment Management LLC grew its position in shares of Certara by 23.0% during the 4th quarter. William Blair Investment Management LLC now owns 5,540,678 shares of the company's stock worth $157,466,000 after buying an additional 1,034,482 shares during the period. Granite Investment Partners LLC acquired a new position in Certara during the second quarter valued at approximately $18,944,000. Finally, Capital World Investors grew its holdings in Certara by 215.5% during the fourth quarter. Capital World Investors now owns 1,254,554 shares of the company's stock valued at $35,654,000 after purchasing an additional 856,959 shares during the period. 77.42% of the stock is owned by institutional investors.
About Certara
(Get Rating)
Certara, Inc provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development.
Further Reading
- Get a free copy of the StockNews.com research report on Certara (CERT)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.
